Fujiwara Yuko, Osborne Daniel A, Walker Michelle D, Wang De-an, Bautista Debra A, Liliom Karoly, Van Brocklyn James R, Parrill Abby L, Tigyi Gabor
Department of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.
J Biol Chem. 2007 Jan 26;282(4):2374-85. doi: 10.1074/jbc.M609648200. Epub 2006 Nov 18.
Sphingosine 1-phosphate (S1P), a naturally occurring sphingolipid mediator and also a second messenger with growth factor-like actions in almost every cell type, is an endogenous ligand of five G protein-coupled receptors (GPCRs) in the endothelial differentiation gene family. The lack of GPCR crystal structures sets serious limitations to rational drug design and in silico searches for subtype-selective ligands. Here we report on the experimental validation of a computational model of the ligand binding pocket of the S1P1 GPCR surrounding the aliphatic portion of S1P. The extensive mutagenesis-based validation confirmed 18 residues lining the hydrophobic ligand binding pocket, which, combined with the previously validated three head group-interacting residues, now complete the mapping of the S1P ligand recognition site. We identified six mutants (L3.43G/L3.44G, L3.43E/L3.44E, L5.52A, F5.48G, V6.40L, and F6.44G) that maintained wild type [32P]S1P binding with abolished ligand-dependent activation by S1P. These data suggest a role for these amino acids in the conformational transition of S1P1 to its activated state. Three aromatic mutations (F5.48Y, F6.44G, and W6.48A) result in differential activation, by S1P or SEW2871, indicating that structural differences between the two agonists can partially compensate for differences in the amino acid side chain. The now validated ligand binding pocket provided us with a pharmacophore model, which was used for in silico screening of the NCI, National Institutes of Health, Developmental Therapeutics chemical library, leading to the identification of two novel nonlipid agonists of S1P1.
鞘氨醇-1-磷酸(S1P)是一种天然存在的鞘脂介质,也是一种在几乎所有细胞类型中都具有生长因子样作用的第二信使,它是内皮分化基因家族中五个G蛋白偶联受体(GPCR)的内源性配体。GPCR晶体结构的缺失给合理药物设计和计算机模拟寻找亚型选择性配体带来了严重限制。在此,我们报告了围绕S1P脂肪族部分的S1P1 GPCR配体结合口袋计算模型的实验验证。基于广泛诱变的验证确定了18个位于疏水配体结合口袋内壁的残基,这些残基与先前验证的三个与头部基团相互作用的残基相结合,现在完成了S1P配体识别位点的图谱绘制。我们鉴定出六个突变体(L3.43G/L3.44G、L3.43E/L3.44E、L5.52A、F5.48G、V6.40L和F6.44G),它们保持野生型[32P]S1P结合,但消除了S1P依赖的配体激活。这些数据表明这些氨基酸在S1P1向其激活状态的构象转变中起作用。三个芳香族突变(F5.48Y、F6.44G和W6.48A)导致S1P或SEW2871产生不同的激活作用,表明两种激动剂之间的结构差异可以部分补偿氨基酸侧链的差异。现在经过验证的配体结合口袋为我们提供了一个药效团模型,该模型用于对美国国立卫生研究院国家癌症研究所(NCI)的发育治疗化学文库进行计算机模拟筛选。从而鉴定出两种新型的S1P1非脂质激动剂。